Masanori Kon

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Hiroaki Yanagimoto · 11 shared papers, 2016–2018 · strength 0.66
   • Paper PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infil… DOI 10.1007/s10147-017-1112-3↗
   • Paper Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients wi… DOI 10.1002/jhbp.447↗
   • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
2. Sohei Satoi · 10 shared papers, 2016–2018 · strength 0.61
   • Paper Redefining the R1 resection in patients with pancreatic ductal adenocarcinoma. DOI 10.1002/jhbp.374↗
   • Paper Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients wi… DOI 10.1002/jhbp.447↗
   • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
3. Tomohisa Yamamoto · 9 shared papers, 2016–2018 · strength 0.51
   • Paper Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients wi… DOI 10.1002/jhbp.447↗
   • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
   • Paper Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemot… DOI 10.1007/s00595-016-1358-9↗
4. So Yamaki · 8 shared papers, 2016–2017 · strength 0.48
   • Paper PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infil… DOI 10.1007/s10147-017-1112-3↗
   • Paper Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients wi… DOI 10.1002/jhbp.447↗
   • Paper Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemot… DOI 10.1007/s00595-016-1358-9↗
5. Satoshi Hirooka · 7 shared papers, 2016–2017 · strength 0.39
   • Paper Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients wi… DOI 10.1002/jhbp.447↗
   • Paper Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemot… DOI 10.1007/s00595-016-1358-9↗
   • Paper Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically define… DOI 10.1002/jhbp.408↗
6. Hironori Ryota · 6 shared papers, 2016–2017 · strength 0.35
   • Paper PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infil… DOI 10.1007/s10147-017-1112-3↗
   • Paper Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemot… DOI 10.1007/s00595-016-1358-9↗
   • Paper Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with … DOI 10.1080/01635581.2016.1134597↗
7. Michiaki Unno · 3 shared papers, 2017–2018 · strength 0.18
   • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
   • Paper Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Ad… DOI 10.1158/2326-6066.cir-17-0386↗
   • Paper Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma … DOI 10.1097/sla.0000000000001705↗
8. Masayuki Sho · 3 shared papers, 2016–2018 · strength 0.16
   • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
   • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
   • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
9. Takahiro Akahori · 3 shared papers, 2016–2018 · strength 0.16
   • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
   • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
   • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
10. Masanao Kurata · 2 shared papers, 2017–2018 · strength 0.12
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
    • Paper Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma … DOI 10.1097/sla.0000000000001705↗
11. Fuyuhiko Motoi · 2 shared papers, 2017–2018 · strength 0.12
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
    • Paper Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma … DOI 10.1097/sla.0000000000001705↗
12. Goro Honda · 2 shared papers, 2017–2018 · strength 0.12
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
    • Paper Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma … DOI 10.1097/sla.0000000000001705↗
13. Yoshiyuki Nakajima · 2 shared papers, 2016 · strength 0.10
    • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
    • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
14. Satoshi Nishiwada · 2 shared papers, 2016 · strength 0.10
    • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
    • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
15. Naoya Ikeda · 2 shared papers, 2016 · strength 0.10
    • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
    • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
16. Minako Nagai · 2 shared papers, 2016 · strength 0.10
    • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
    • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
17. Shoichi Kinoshita · 2 shared papers, 2016 · strength 0.10
    • Paper Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreat… DOI 10.1002/jhbp.318↗
    • Paper Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) i… DOI 10.1007/s00280-015-2928-z↗
18. Pavel Viktorovich Markov · 1 shared paper, 2016 · strength 0.10
    • Paper Redefining the R1 resection in patients with pancreatic ductal adenocarcinoma. DOI 10.1002/jhbp.374↗
19. Yuki Hashimoto · 1 shared paper, 2017 · strength 0.07
    • Paper Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients wi… DOI 10.1002/jhbp.447↗
20. Yoshiaki Murakami · 1 shared paper, 2018 · strength 0.07
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
21. Ken‐ichi Okada · 1 shared paper, 2018 · strength 0.07
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
22. Hiroki Yamaue · 1 shared paper, 2018 · strength 0.07
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
23. Kenichiro Uemura · 1 shared paper, 2018 · strength 0.07
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
24. Hirochika Toyama · 1 shared paper, 2018 · strength 0.07
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗
25. Ippei Matsumoto · 1 shared paper, 2018 · strength 0.07
    • Paper Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic duc… DOI 10.1016/j.pan.2017.11.005↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.